We have examined the constitutive and inducible secretion of platelet-derived growth factor (PDGF)-like proteins in a variety of human hemopoietic cell lines. The highest levels of secreted protein were noted in four human erythroleukemia lines which, in addition to erythroid lineage markers, express one or more megakaryocytic lineage markers. Induction of these lines by 12-O-tetradecanoylphorbol-13-acetate enhanced the expression of megakaryocytic markers and increased secretion of PDGF-like proteins several fold. In concert with these changes, there was significant induction of c-sis/PDGF-B messenger RNA (mRNA) expression in all lines, whereas one line showed significant concurrent induction of PDGF-A mRNA expression. Whether PDGF-like secretion is part of the stem cell-like phenotype displayed by these lines or is secondary to their leukemic transformation remains to be determined. Nevertheless, these lines provide new cellular models for studying the expression and function of PDGF analogs in hemopoietic cells.
Introduction
Platelet-derived growth factor (PDGF)' is a potent mitogen for many connective tissue cells in culture (1) (2) (3) (4) . PDGF exerts its function by binding to specific cell surface receptors on responsive cells (5) and thereby triggering a number of intracellular events culminating in cell division (6) . A major source of PDGF is the a-granules of platelets. PDGF released from activated platelets in vivo could play a role in normal wound repair (1, 2, 4) and in the development of lesions of atherosclerosis (4, 7) . In addition to platelet-stored PDGF, which appears to be synthesized earlier in megakaryocytes (8, 9) , several other cellular sources of PDGF-like molecules have been identified. These include cultured endothelial cells (10, 1 1), activated macrophages (12) (13) (14) , newborn rat aortic smooth muscle cells (15) , and human cytotrophoblasts ( 16) , all of which secrete PDGF-like molecules in culture. Furthermore, cells transformed by a wide variety of transforming agents that do not themselves encode for a PDGFlike molecule, secrete a PDGF-like molecule into their media Receivedfor publication 4 August 1986. 1 . Abbreviations used in this paper: FITC, fluorescein isothiocyanate; GP, glycoprotein; HEL, human erythroleukemia; PDS, plasma-derived serum; PDGF, platelet-derived growth factor, PMA, phorbol 12-myristate 13-acetate; TPA, 12-O-tetradecanoylphorbol 13-acetate; vWF, von Willebrand factor. (17) (18) (19) . Thus , it has been speculated that PDGF may contribute not only to the process of transformation and uncontrolled proliferation of some malignant cells, but, in addition, to processes of normal proliferation and differentiation.
Because synthesis of PDGF is associated with cells of megakaryocytic lineage, we examined in the present study whether hemopoietic cell lines previously found to express one or more megakaryocytic markers (20-23) are capable of synthesizing or secreting PDGF. Parallel observations with other nonlymphoid hematopoietic cell lines not expressing these markers were also carried out. Inasmuch as an enhancement of megakaryocytic marker expression has been observed after addition of certain compounds (23), we also determined whether the same agents could augment production or release of PDGF.
Our results show that several hemopoietic cell lines produce PDGF analogs by protein and messenger RNA (mRNA) measurements, especially after induction. They also establish an association between PDGF secretion and megakaryocytic marker expression and a coordinate enhancement of both of these features by addition of phorbol diesters. Whether PDGF is part of the cells' megakaryocytic differentiation program, or whether it is a manifestation oftheir hemopoietic immaturity and/or their transformed nature is unclear and requires further study. Our data, nevertheless, provide new information about in vitro activation of PDGF-A and PDGF-B sequences (coding for A or B chain of PDGF) and secretion of PDGF-like molecules in hematopoietic cell lines.
Methods
Hematopoietic cell lines. We selected 11 permanent human leukemic cell lines for evaluation. These represent a spectrum of nonlymphoid hematopoietic cell lines in various stages ofdifferentiation (Table I) TPA was added at a concentration of 1.6 X l-7 M, and an equal number of cells were incubated without TPA. DMSO was used as 1% solution in media + PDS. After a 48-h incubation in the presence of the inducer, the mixture of cells and medium were separated by centrifugation, the pelleted cells were pooled and counted, and both the cells and the supernatant medium were processed for determination of PDGF levels by radioreceptor assay. If the cells became adherent during the 2-d incubation, cold phosphate-buffered saline (PBS) was added to the flasks, and they were refrigerated for 1-2 h with gentle shaking and sometimes scraped with a sterile cell scraper to recover all the cells. The cells were counted in a hemocytometer and the total number of cells as well as viable cells were estimated by trypan blue dye exclusion. Cell lysates were prepared by repeated freezing and thawing in PBS. In selected experiments, media from TPA-treated OCIM2 cells were collected in the presence and absence of actinomycin D (2.5 ug/ml) or cycloheximide (5 ug/ml). The media were concentrated -10-fold using Amicon ultrafiltration and a YM-l0 membrane (Amicon Corp, Danvers, MA). Assayfor PDGF receptor competitive activity. Subconfluent cultures of human adult foreskin fibroblasts or juvenile human skin fibroblasts (American Type Culture Collection) were prepared in 2-cm2 24-well culture dishes (Costar, Cambridge, MA) in 1% human PDS and used for determination ofPDGF levels in test samples using the radioreceptor assay described previously (33) . Briefly, the cultures were rinsed once with binding rinse (ice-cold PBS containing I mg/ml bovine serum albumin [BSA]) and then incubated on an oscillating table with 0.5 or I ml per well of binding media containing the test sample or standard concentrations of PDGF. After 3 h, the test samples were aspirated, and the wells rinsed once with binding rinse, and incubated for one additional hour at 4VC with binding medium containing 0.5 ng/ml '25I-PDGF.
Binding was terminated by washing three times with binding rinse, and cell-associated '25I-PDGF was extracted with 1% Triton X-100 in 0.1% BSA. Highly purified PDGF was prepared as described (34) and was radioiodinated to a specific activity of 20,000-40,000 cpm/ng (33) .
RNA extraction, Northern and dot blot hybridization. Cells were homogenized in guanidine thiocyanate (Eastman Kodak Co., Rochester, NY) and subjected to ultracentrifugation through a cesium chloride cushion as described by Chirgwin et al. (35) . The RNA pellet was suspended in 0.3 ml of water. Total RNA was enriched for polyadenylatecontaining RNA by one cycle of oligo dT cellulose affinity chromatography (36) . RNA concentration was estimated by OD 260 determination.
For Northern blot analysis, portions (5 Ag) ofpolyadenylated RNA were subjected to electrophoresis in formaldehyde gels and transferred to nitrocellulose filters as described (37). The filter was baked for 2 hat 80'C and then hybridized to a gel-purified and nick-translated 1.7-kb Bam csis fragment representing the 3' exon of human proto-oncogene c-sis (38, 39) or to the PDGF-A chain cDNA probe (clone Dl, 1.3 kb) (40) . Hybridizations were performed in 50% formamide/ I0% dextran sulfate/ 0.45 M NaCl/0.045 M trisodium citrate for 36 h at 420C. After hybridization filters were washed in 0.1% SDS/5 mM NaCI/1.5 mM trisodium citrate at 500C, dried, and exposed to Kodak XAR-5 film. Sizes of transcripts in kilobases were determined by comparison with 28S (5.0 kb) and 18S (2.0 kb) ribosomal RNA bands visualized by ethidium bromide staining of a marker lane excised from each gel before nitrocellulose transfer. For dot blots polyadenylated RNA was diluted in 100 Al of water containing 6X standard saline citrate (SSC) and 2.2 M formaldehyde and then heated for 15 min at 60°C. The samples were chilled on ice and then applied with HybriDot manifold (Bethesda Research Laboratories, Gaithersburg, MD) to a nitrocellulose filter previously soaked in 20 X SSC. The filter was dried under a heat lamp, baked, hybridized, and washed exactly as described above.
Immunofluorescence studies. Immunofluorescence studies were carried out in cell lines before and after the addition of TPA or DMSO. Treated cells were harvested 48 h after treatment, washed in PBS + 1% BSA + 0.01% sodium azide, and subjected to specific antibody labeling as follows. To a small aliquot of cells a few X (10-50) of an appropriately diluted monoclonal antibody (either semipurified or as ascites fluid) was added. After a 30-min incubation at room temperature, the cells were washed three times with PBS, then a small amount of appropriately 
Results
Production ofPDGF-like molecules by 1I hematopoietic cell lines before and after induction with TPA. Media and cell extracts of the nonlymphoid hematopoietic cell lines listed in Table I were evaluated for production of functional PDGF-like molecules by PDGF radioreceptor assay (33) . All cell lines were free of mycoplasma and were preconditioned in 1% human PDS known to be free of detectable levels of PDGF. PDGF levels were determined on media from cells maintained for 48 h in the presence or absence of 1.6 X l0-7 M TPA. The data are illustrated in Coordinate expression ofplatelet-megakaryocytic markers and PDGF-like secretion. All the cell lines included in our survey were tested for the presence of surface membrane glycoproteins characteristic for cells of platelet-megakaryocytic origin (Fig. 1) . Polyclonal and monoclonal antibodies against the complex GP lIb/IIla (Fig. 2) and GP Ib (Fig. 3) , as well as monoclonal antibodies reacting specifically with either GP lIb or GPIIIa (Fig.  3) , were employed in indirect immunofluorescence assays. In accord with previous studies on human erythroleukemia (HEL) and K562 cells (22, 23) , high reactivity against GP IIb/IIIa was observed with all HEL-derived sublines, whereas relatively less reactivity was present in the K562 sublines, (K562(S) and K562(C-16)) ( Fig. 2 and data not shown) . In addition, the present studies uncovered reactivities against the GP IIb/IIIa complex, using both polyclonal and monoclonal antibodies in two additional lines: OCIM2 and KG-la, whereas the remainder were negative. GP lb was detected only in HEL cells (Fig. 3) , whereas the presence of intracellular vWF antigen was noted in some cells from both the HEL cell line and the OCIM2 and in none of the remaining cell lines (Table I ). In general, the expression of platelet glycoproteins (specifically GP I~b/IIIa or GP lIIa) was enhanced after treatment of cells with either TPA or DMSO, and the augmentation of reactivity was more pronounced when FCS-maintained cells were treated as opposed to cells treated in the presence of PDS (data not shown). The appearance of few positive cells with anti-GP IIb/IIIa was also noted in U-937 cells after TPA treatment (when polyclonal anti-GP Ilb/lIIa was used, more positive cells were seen). The most significant increase in the expression ofGP IIb/IIIa compared with pretreatment levels was observed in K562(S) cells (Fig. 2) . This increase concerned solely GP IIIa, as independent labeling with only anti-GP Ilb or only anti-GP lIIa showed (data not shown). By contrast, induced HEL cells displayed enhancement in both GP Ilb and GP IIa (Fig. 3) . GP lb was not induced de novo in any of the lines, whereas in HEL cells, TPA-induced changes in preexisting GP lb reactivity were different with different antibodies used (Fig. 3) , suggesting possible conformational effects. In addition to differences in certain cell marker reactivity using a single inducer, there were differences between the two inducers, TPA and DMSO, in their ability to particular antibody (Fig. 2) . From the data presented in Fig. 1 , it is apparent that cell lines with no significant expression of platelet glycoproteins (constitutive or induced) showed very low levels of PDGF-like secretion, even after induction. Nevertheless, a quantitative correlation between the abundance of plateletmegakaryocytic marker expression and PDGF secretion was not found. Characteristics ofinduced secretion ofPDGF-like molecules by three cell lines: OCIM2, K562(S) and HEL. The kinetics of accumulation in culture medium of the PDGF-like molecules by the three highest producers were evaluated over the first 48 h with or without the addition of TPA. As shown in Fig. 4 , the rate ofPDGF secreted into the medium, expressed as nanograms/ 106 cells per 6 h remained fairly constant in noninduced cells. However, after induction with TPA, this rate was significantly increased and reached maximal levels at approximately 24 h. In a separate experiment with OCIM2 only, maximal levels were maintained for 6 d and resulted in continual accumulation of PDGF-like molecules in the medium (Fig. 5) . These kinetic data on PDGF accumulation in media after TPA induction suggested that de novo protein synthesis is required. Indeed, when cycloheximide or actinomycin D were continuously present in OCIM2 treated with TPA (Table II) , synthesis of PDGF-like molecules was significantly blocked, although cell viability or induction of adherence by TPA was unaffected (data not shown).
A separate experiment was designed to determine whether production of PDGF-like molecules was dependent on cell growth and DNA synthesis. As a result of treatment with TPA or DMSO, growth of the erythroleukemic cells is essentially abrogated. To determine whether the growth status of the cells affected production of PDGF-like molecules, the proliferative activity of HEL cells was independently modulated by two different approaches: either it was inhibited by the addition ofthymidine (2 mM for 48 h) or the cells were examined at different stages of growth: stationary phase (at high cell densities) vs. exponential cell growth. As shown in Table III , production of PDGF-like molecules by HEL cells was independent of growth rate. Induction by TPA or DMSO was comparable in a growing state or in a state in which cell growth was markedly restricted. Therefore, absence of proliferation, commonly observed after treatment with TPA, cannot explain release of PDGF-like material.
Demonstration of c-sis/PDGF-B-and of PDGF-A-related transcripts in hemopoietic cell lines before and after addition of TPA. To determine whether synthesis and secretion of PDGFlike molecules by the erythroleukemic cells is associated with csis expression (B-chain of PDGF as described by Johnson et al.
[44]), preparations of poly A(+) RNA from untreated K562(S), OCIM2, HEL, HL-60, and U937 cells were tested in dot blot and in Northern blot hybridization experiments, using as a probe a 1.7-kb cloned fragment representing the 3' exon of human csis (37). Virtually undetectable levels of c-sis transcripts were found in all the lines tested before induction (Fig. 6 and data not shown). After addition of TPA, however, the highest induc- were determined by radioreceptor assay as described in Methods, and the data have been normalized to final cell number at 48 h and to the amount released over a 6-h period.
tion ofc-sis transcription was seen in K562(S) and OCIM2. The size ofthe c-sis-related transcripts (4 kb) in these cells was similar to that previously described for human cells (37, 38). Peak levels were found at 12 h post-TPA addition in K562(S) cells and there was a decrease 24 and 48 h later. By contrast, for OC 1 M2 peak levels were not reached until 24 h and were maintained at about the same level until 48 h. Induction of c-sis transcription in HEL cells was -10-fold less than OCIM2 cells (data not shown), and U-937 line showed a significant induction of c-sis expression (data not shown). PDGF-A mRNA transcripts (40) were not detectable in all lines before induction, but they were strongly induced in K562(S) cells and less so in OCIM2 after TPA addition ( Fig. 7 and data not shown). Although the significance ofthe coexpression of megakaryocytic and erythroid markers within the same cell population is at present unclear (45) , it has been possible to modulate these two phenotypes in vitro, independently or in combination. For example, treatment of HEL or K562 cells with TPA abrogates the expression and inducibility oferythroid markers (46, 47) , whereas it enhances the expression of megakaryocytic markers (23) . In this regard our present data on amplification of megakaryocytic markers, including the previously unstudied lines OCIM2, K562(S), and KG-la, expand initial observations made in HEL and K562 cells. Evaluation of megakaryocytic/platelet antigen expression by different antibodies than the ones used previously (23) uncovered independence in the expression and regulation of the various platelet glycoproteins. For example, GP lb was detected in HEL cells only, and K562(S) cells expressed virtually only GP IIa, either before or after induction; by contrast, both GP Ilb and GP Ila were induced in HEL and OCIM2 cells.
In addition to enhancement of surface megakaryocytic markers in response to TPA, a major feature of TPA induction examined in detail here was the augmentation in secretion of a PDGF-levels were determined by radioreceptor assay as described in 49, 50) , and they both synthesize several ofthe platelet-megakaryocyte proteins (i.e., GP IIb/IIIa, factor VIII, vWF, or platelet factor 4) (51, 52). A notable difference, however, is that thrombin (53) and inactive phorbol (11) promoted PDGF release in endothelial cells but not in erythroleukemic lines (Table  II) . Such differences may hinge upon structural dissimilarities among PDGF forms produced by the two cell types.
The significance of PDGF-like proteins produced by erythroleukemic cells is presently unclear. Several possible interpretations can be forwarded, however. One possibility is that the PDGF-like activity secreted by these cells is part of their megakaryocytic differentiation program; the constitutive secretion of PDGF and other megakaryocytic proteins and their coordinate enhancement seen with the same inducers supports this postulate. Also, the recently reported constitutive and inducible PDGF-like secretion by one leukemic line expressing megakaryocytic markers is in agreement with this notion (54 To decide between these possibilities and to understand the significance of secreted PDGF, further studies on the structural and functional features of PDGF-like activity elaborated by these hemopoietic cell lines, as compared with PDGF analogs secreted by other cells, are required. Nevertheless, our data on the expression ofboth A-and B-chain genes (and secretion ofPDGFlike molecules) provide model systems for studying events associated with PDGF analog secretion by hemopoietic cells.
